文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-PSMA PET/CT与18F-NaF PET/CT在新诊断高危前列腺癌分期与治疗中的前瞻性单中心研究

18F-PSMA PET/CT Versus 18F-NaF PET/CT for Staging and Treating Newly Diagnosed High-Risk Prostate Cancer: A Prospective Single-Center Study.
PubMed 文献 · J Nucl Med · 2025-12-03

该前瞻性单中心研究纳入160例新诊断高危前列腺癌患者,均在接受治疗决策前3周内完成18F-NaF PET/CT与18F-PSMA-1007 PET/CT。先仅依据NaF结果制定分期与治疗,后揭示PSMA结果并多学科重新评估,发现25%患者转移分期改变、13%治疗方案改变,PSMA PET/CT显著影响分期迁移与治疗意图。

要点

  • 18F-PSMA PET/CT使25%患者转移分期重新分类,其中24%分期更晚、1%更早。
  • 淋巴结转移是分期改变主因:19%患者CT无淋巴结受累而PSMA发现淋巴结病。
  • 盆腔外淋巴结转移率从16%升至27%,13%患者治疗方案随之改变。

核心结论

  • 使用18F-PSMA PET/CT导致显著的转移分期迁移,并在相当比例患者中影响治疗计划。

研究设计与样本

  • 前瞻性单中心研究纳入160例新诊断高危前列腺癌患者,均在3周内完成18F-NaF PET/CT与18F-PSMA-1007 PET/CT。
  • 先隐藏18F-PSMA PET/CT结果,仅基于18F-NaF PET/CT制定分期与治疗决策;后续揭示PSMA结果并在多学科研究环境中重新评估分期与治疗计划。
  • 采用Wilcoxon符号秩检验分析分期与治疗意图差异。

主要发现

  • 18F-PSMA PET/CT后40例(25%)患者转移分期被重新分类,其中24%分期更晚、1%分期更早(P < 0.001)。
  • 淋巴结转移贡献了多数改变:30例(19%)CT无淋巴结受累的患者在18F-PSMA PET/CT上发现淋巴结病。
  • 盆腔外淋巴结转移率从16%增至27%。
  • 21例(13%)患者治疗方案改变,主要反映从治愈性意图转向非治愈性意图或转向更强化的全身治疗(P = 0.001)。

临床怎么用

  • 在新诊断高危前列腺癌的分期与治疗决策中,可考虑以18F-PSMA PET/CT替代18F-NaF PET/CT以更准确识别淋巴结及远处转移。
  • PSMA PET/CT结果可能改变转移分期与治疗意图,建议在多学科框架下结合PSMA结果重新评估治疗计划。

局限性

  • 本研究为前瞻性单中心设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiolabeled prostate-specific membrane antigen (PSMA) PET/CT has demonstrated superior diagnostic accuracy for staging prostate cancer (PC) compared with conventional imaging modalities. However, the clinical impact of replacing 18F-NaF PET/CT with PSMA PET/CT in high-risk PC remains underexplored. Methods: In this prospective single-center study, 160 patients with newly diagnosed high-risk PC underwent both 18F-NaF PET/CT and 18F-PSMA-1007 PET/CT within 3 wk. The 18F-PSMA PET/CT results were initially withheld; therefore, staging and treatment decisions were based solely on 18F-NaF PET/CT. At a later time point, the 18F-PSMA PET/CT findings were revealed, and staging and treatment plans were reassessed in a multidisciplinary research setting. Differences in staging and treatment intent were analyzed using Wilcoxon signed-rank tests. Results: The metastatic stage was reclassified for 40 patients (25%) after 18F-PSMA PET/CT, with 24% classified as having a more advanced stage and 1% having a less advanced stage (P < 0.001). Lymph node metastases accounted for most changes: 30 patients (19%) with no nodal involvement on CT were found to have nodal disease on 18F-PSMA PET/CT, and the rate of extrapelvic lymph node metastases increased from 16% to 27%. Treatment plans were changed for 21 patients (13%), primarily reflecting a shift from curative to noncurative intent or toward more intensified systemic therapy (P = 0.001). Conclusion: The use of 18F-PSMA PET/CT resulted in significant metastatic stage migration and influenced treatment planning in a substantial proportion of patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Madsen C, Zacho HD, Fuglø D, et al. 18F-PSMA PET/CT Versus 18F-NaF PET/CT for Staging and Treating Newly Diagnosed High-Risk Prostate Cancer: A Prospective Single-Center Study. J Nucl Med. 2025. PMID: 41067861. doi:10.2967/jnumed.125.270822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。